Xeris Biopharma Holdings Inc
NASDAQ:XERS
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
Record Revenue: Xeris delivered record Q3 total product revenue of $74 million, up 40% year-over-year.
Guidance Raised: The company increased the lower end of its 2025 total revenue guidance to $285–290 million, representing 42% growth at the midpoint.
Profitability Milestone: Xeris reported positive net income for the first time in its history, along with strong adjusted EBITDA of $17.4 million.
RECORLEV Momentum: RECORLEV revenue more than doubled to $37 million (up 109% YoY), fueled by 108% patient growth.
Ongoing Investments: Xeris is expanding its commercial footprint, with increased SG&A and R&D spend expected to support future growth, including the XP-8121 Phase III trial starting in H2 2026.
Sustained Margin Strength: Gross margin improved to 85% due to better product mix.
